<br><br>**The Power of Amgen's Q4 Results A Modest Uptick in Shares as MariTide Shines**<br><br>Amgen, a leading biotech company based in California, recently released its fourth-quarter financial results, which exceeded Wall Street expectations. This modestly boosted the company's shares, sending a positive signal to investors.<br><br>**Revenue and Earnings Per Share**<br>Amgen's quarterly revenue rose 9% year-over-year to $9.9 billion, surpassing analysts' estimates of $9.5 billion. Adjusted earnings per share were little changed at $5.29, yet still managed to beat expectations of $4.73.<br><br>**MariTide and Obesity**<br>Amgen's experimental weight-loss drug MariTide remains a key focus area for the company. With six Phase 3 trials currently underway across obesity-related conditions, including heart disease and sleep apnea, investors are eager to see how this therapy will perform. The company also plans to begin Phase 3 studies of MariTide for diabetes patients in 2026.<br><br>**A Paradigm-Changing Opportunity**<br>During a conference call, Amgen's commercial operations chief, Murdo Gordon, emphasized the potential impact of MariTide on the market. He highlighted the dissatisfaction with weekly GLP-1s, such as Novo Nordisk's Wegovy, and praised MariTide as a paradigm-changing opportunity for patients seeking new treatment options.<br><br>**Other Weight-Loss Initiatives**<br>Amgen is also enrolling obese adults into a Phase 1 trial of another weight-loss drug candidate, AMG513. This further underscores the company's commitment to developing innovative solutions in this space.<br><br>**Outlook and Guidance**<br>For 2026, Amgen expects adjusted earnings per share to range from $21.60 to $23.00, while analysts estimate $22.09 per share. The company forecasts revenue of $37 billion to $38.4 billion, compared with analyst expectations of $37.1 billion.<br><br>**Product Sales**<br>Fourth-quarter product sales rose 10% by volume, driven by higher volumes and a 7% quarter-over-quarter growth rate. Repatha, Amgen's cholesterol drug, saw a significant increase in sales, jumping 44% to $870 million. Enbrel, on the other hand, experienced a 48% decline in sales due to lower prices paid for Medicare.<br><br>**Tavneos and FDA**<br>Amgen also addressed concerns surrounding Tavneos, which was requested by the US Food and Drug Administration (FDA) be withdrawn from the US market. The company remains confident in the drug's efficacy and has informed the FDA that it does not intend to withdraw it.<br><br>**Conclusion**<br>Amgen's Q4 results demonstrate the company's continued commitment to driving innovation and growth in the biotech space. With MariTide and other weight-loss initiatives, Amgen is poised for success in the years ahead.<br><br>**Historical Influence**
--
Disclaimer:
*The information
in this electronic message is privileged and
confidential, intended only
for use of the individual or entity named as
addressee and recipient.
If you are not the addressee indicated in this
message (or responsible
for delivery of the message
to such person), you
may not copy, use, disseminate or deliver this
message. In such case, you
should immediately delete this e-mail and
notify the sender by reply
e-mail. Please advise immediately if you or
your employer do not consent
to Internet e-mail
for messages of this kind. Opinions, conclusions and
other information
expressed in this message are not given, nor endorsed by
and are not the
responsibility of *USTP* unless otherwise indicated by an
authorized representative of *USTP* independent of this message.*
0 Comments